| Ytd | -21.31% | |
| 1y | 11.19% |
| Open | 17.84 | Prev Close | 17.89 | Low | 17.11 | High | 17.86 | Mkt Cap | 678.79M |
| Vol | 147.73K | Avg Vol | 341.24K | EPS | -1.63 | P/E | -10.98 | Forward P/E | -24.29 |
| Beta | 0.77 | Short Ratio | 2.68 | Inst. Own | 39.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.57 | 200-d Avg | 18.27 | 1yr Est | 33.25 |
CBLL News
SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m
Study published in leading critical care journal shows that higher AI-detected seizure burden is ass
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a me
CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued moment
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook,
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus E
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a me
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a
CeriBell (NASDAQ: CBLL) executives outlined the company's 2026 priorities and growth drivers during
CeriBell (NASDAQ: CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S.
Shares of CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) have earned a consensus rating of "Moderat
CeriBell (NASDAQ: CBLL - Get Free Report) and Allurion Technologies (NYSE: ALUR - Get Free Report) a
CeriBell (NASDAQ: CBLL - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both smal
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus E
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m
